Abbvie Inc. (NYSE:ABBV) Q4 2023 Adjusted Profit, Revenue Rises; Sets Outlook for 2023

/ / Health Care /

Abbvie Inc. (NYSE:ABBV) reported Q4 adjusted earnings Thursday of $3.60 per diluted share,Analysts polled by Capital IQ expected $3.58. Revenue for the quarter ended Dec. 31 was $15.12 billion, Analysts surveyed by Capital IQ expected $15.30 billion. For the full year of 2023, the company is expecting adjusted earnings of $10.70 to $11.10 per diluted share. Analysts polled by Capital IQ are expecting $11.68.

Abbvie Inc. (NYSE:ABBV) Q4 2023 Adjusted Profit, Revenue Rises; Sets Outlook for 2023 Read Post »

Abbvie Inc. (NYSE:ABBV) Net Revenues grew 1.6% YoY to $15.121 Billion in Q4 2022

/ / Health Care /

February 9, 2023 – Abbvie Inc. (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2022. reported Q4 adjusted earnings  of $3.60 per diluted share, Analysts polled by Capital IQ expected $3.58. Revenue for the quarter ended Dec. 31 was $15.12 billion, Analysts surveyed by Capital IQ expected $15.30 billion. For the full year of 2023, the company is expecting adjusted earnings of $10.70 to $11.10 per diluted share. Analysts polled by Capital IQ are expecting $11.68. AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results Reports Full-Year Diluted EPS of $6.63 on a GAAP Basis, an Increase of 2.8 Percent; Adjusted Diluted EPS of $13.77, an Increase of 16.4 Percent; Delivers Full-Year Net Revenues of $58.054 Billion, an Increase of 3.3 Percent on a Reported Basis and 5.1 Percent on an Operational Basis。 Reports Fourth-Quarter Diluted EPS of $1.38 on a GAAP Basis, a decrease

Abbvie Inc. (NYSE:ABBV) Net Revenues grew 1.6% YoY to $15.121 Billion in Q4 2022 Read Post »

Abbott (NYSE:ABT) Agreed to acquire Cardiovascular Systems for $890 million

/ / Health Care /

Shares rose 47 percent to $19.58 in early trading after Abbott (NYSE:ABT) agreed to buy Cardiovascular Systems (CSII) for $890 million, or $20 per share, MarketWatch reported. Termao Cardiovascular Systems is a leader in percutaneous atherectomy of transluminal plaques, a minimally invasive treatment for plaque buildup in the arteries. Abbott said the deal’s impact on its recently issued 2023 EPS guidance is neutral.

Abbott (NYSE:ABT) Agreed to acquire Cardiovascular Systems for $890 million Read Post »

Pepsico, Inc. (NASDAQ: PEP) reported Q4 2022 revenue of $28.00 billion, up 11% year-over-year

/ / Consumer Staples /

Pepsico, Inc. (NASDAQ: PEP)  reported Q4 non-GAAP earnings Thursday of $1.67 per diluted share, up from $1.53 a year earlier. Analysts polled by Capital IQ expected $1.65. Revenue for the quarter ended Dec. 31 was $28 billion, up from $25.25 billion a year earlier. Analysts surveyed by Capital IQ expected $26.82 billion. For 2023, the company is expecting core earnings of $7.20 per share. Analysts surveyed by Capital IQ are expecting $7.30. The company said it expects a 6% increase in organic revenue for full-year 2023. Total cash returns to shareholders are expected to be $7.7 billion, including dividends of $6.7 billion and share repurchases of $1 billion. Further, the company raised its annualized dividend to $5.06 per share from $4.60. The increase is effective with the dividend expected to be paid in June.

Pepsico, Inc. (NASDAQ: PEP) reported Q4 2022 revenue of $28.00 billion, up 11% year-over-year Read Post »

Pepsico, Inc. (NASDAQ:PEP) expects 2023 core EPS of $7.20 below market estimates

/ / Consumer Staples /

Pepsico, Inc. (NASDAQ: PEP) reported fourth-quarter 2022 net revenue of $28.00 billion, up 11% year-over-year, and $26.88 billion in pro forma, and core earnings per share of $1.67, compared to $1.53 in the year-ago quarter, compared to $1.64 pro forma. The company expects core EPS of $7.20 in 2023 versus $7.26 market estimate.

Pepsico, Inc. (NASDAQ:PEP) expects 2023 core EPS of $7.20 below market estimates Read Post »

Pepsico, Inc. (NASDAQ:PEP) reported Q4 2022 revenue of $28.00 billion, up 11% year-over-year

/ / Consumer Staples /

Pepsico, Inc. (NASDAQ: PEP) reported fourth-quarter 2022 net revenue of $28.00 billion, up 11% year-over-year, and $26.88 billion in pro forma, and core earnings per share of $1.67, compared to $1.53 in the year-ago quarter, compared to $1.64 pro forma. The company expects core EPS of $7.20 in 2023 versus $7.26 market estimate.

Pepsico, Inc. (NASDAQ:PEP) reported Q4 2022 revenue of $28.00 billion, up 11% year-over-year Read Post »

Credit Suisse (NYSE:CS) revenue of CHF 3.06 billion in Q4 2022, compared to CHF 4.582 billion previously

/ / Financials /

Credit Suisse Group Ag (NYSE:CS) had net revenue of CHF 3.06 billion in the fourth quarter of 2022, compared to CHF 4.582 billion in the previous quarter, and a net loss of CHF 1.39 billion. In 4Q22, we recorded a net loss attributable to shareholders of CHF 1,393 million. As of the end of 4Q22, our CET1 ratio was 14.1%. In 4Q22, Credit Suisse reported a net loss attributable to shareholders of CHF 1,393 million, compared to a net loss attributable to shareholders of CHF 2,085 million in 4Q21 and a net loss attributable to shareholders of CHF 4,034 million in 3Q22. In 4Q22, Credit Suisse reported a loss before taxes of CHF 1,315 million, compared to a loss before taxes of CHF 1,664 million in 4Q21 and a loss before taxes of CHF 342 million in 3Q22. Adjusted loss before taxes in 4Q22 was CHF 1,015 million compared to adjusted income before taxes of CHF 328 million in

Credit Suisse (NYSE:CS) revenue of CHF 3.06 billion in Q4 2022, compared to CHF 4.582 billion previously Read Post »

GSK plc (NYSE:GSK) Sales grew 19% YoY to £29.3 billion in 2022

/ / Health Care /

1 February 202 GSK plc (NYSE:GSK)  delivers strong 2022 performance with full year sales of £29.3 billion。 +19% AER, +13% CER; Total EPS 371.4p >100% Adjusted EPS of 139.7p +27% AER, +15% CER from continuing operations。 Sales of £29.3 billion +19% AER, +13% CER. Sales +15% AER, +10% CER excluding COVID-19 solutions。 Specialty Medicines £11.3 billion +37% AER, +29% CER; HIV +20% AER, +12% CER; Oncology +23% AER, +17% CER; Immuno-inflammation and other specialty +29% AER +20% CER; COVID-19 solutions (Xevudy) sales £2.3 billion。 Vaccines £7.9 billion +17% AER, +11% CER; Shingrix £3 billion +72% AER, +60% CER。 Total continuing operating margin 21.9%. Total EPS 371.4p > 100% primarily reflecting the gain from discontinued operations arising on the demerger of the Consumer Healthcare business. Total continuing EPS 110.8p +34% AER, +18% CER。 Adjusted operating margin 27.8%. Adjusted operating profit growth +26% AER, +14% CER. This included a decline in growth from COVID-19

GSK plc (NYSE:GSK) Sales grew 19% YoY to £29.3 billion in 2022 Read Post »

Scroll to Top